# Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

> **NCT06847724** · PHASE3 · RECRUITING · sponsor: **Sandoz** · enrollment: 175 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** CYB704
- **BIOLOGICAL:** Ocrevus-EU
- **BIOLOGICAL:** Ocrevus-US

## Key facts

- **NCT ID:** NCT06847724
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2026-10-14
- **Final completion:** 2029-10-14
- **Target enrollment:** 175 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06847724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06847724, "Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06847724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*